Inhibitors of MAdCAM-1-mediated interactions and methods of use

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 19, 530300, 530331, A61K 3800, A61K 3806, A61K 3807

Patent

active

060373245

ABSTRACT:
The present invention provides novel compounds comprising peptide sequences which mimic the conserved amino acid motif LDTSL and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human .alpha.4.beta.7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compound of the present invention.

REFERENCES:
patent: 5134121 (1992-07-01), Mobley
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5358934 (1994-10-01), Borovsky
patent: 5436221 (1995-07-01), Kitaguchi
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5728677 (1998-03-01), Wallner et al.
patent: 5728802 (1998-03-01), Barrett et al.
patent: 5756449 (1998-05-01), Andersen et al.
Martens et al. J. Biol. Chem., 270: 21129-21136, Oct. 1995.
U.S.S.N. 08/498,237 entitles Cell Adhesion Inhibitors, by Lin et al., filed on Jul. 11, 1995.
Shroff, H. N., et al., "Small Peptide Inhibitors of .alpha..sub.4 .beta..sub.7 Mediated MAdCAM-1 Adhesion to Lymphocytes," Bioorganic & Medicinal Chemistry Letters, 6(21):2495-2500 (1996).
Komoriya, A. et al., "The Minimal Essential Sequence for a Major Cell Type-Specific Adhesion Site (CS1) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin is Leucine-Aspartic Acid-Valine," The Journal of Biological Chemistry, 226(23):15075-15079 (1991).
Yongjun Duan and R. A. Laursen, "Protease Substrate Specificity Mapping Using Membrane-Bound Peptides," Analytical Biochemistry, 216:431 438 (1994).
van Amerongen, A. et al., "Peptide Reactive with a Transmission-Blocking Monoclonal Antibody Against Plasmodium-falciparum Pfs25: 2000-Fold Affinity Increase by PEPSCAN-Based Amino Acid Substitutions," Peptide Research, 5(5):269-274 (1992).
Stura, E. A. et al., "Crystallization of an Intact Monoclonal Antibody (4B7) Against Plasmodium Falciparum Marlaria with Peptides from the Pfs25 Protein Antigen," Acta. Cryst. D50:556-562 (1994).
Stura, E. A. et al., "Crystallization Sequence and Preliminary Crystallographic Data for Transmission-Blocking Anti-Malaria Fab 4B7 with Cyclic Peptides from the Pfs25 Protein of P. Falciparum," Acta. Cryst. D50:535-542 (1994).
Stura, E. A. et al., "Crystallization of Neutralizing Malaria Immunoglobulin with Linear and Cyclic Peptides," Pept. Chem. Struct. Biol., Proc. Am. Pept. Symp. 13th, Editor, Hodges, Robert S. and Smith, John A., pp. 817-819 (1994).
Briskin, M. J. et al., "MAdCAM-1 has Homology to Immunoglobulin and Mucin-Like Adhesion Receptors and to lgA1," Nature, 363:461-464 (Jun. 3, 1993).
Wang, J. H., et al., "The Crystal Structure of an N-terminal Two-Domain Fragment of Vascular Cell Adhesion Molecule 1 (VCAM-1): A Cyclic Peptide Based on the Domain 1 C-D Loop can Inhibit VCAM-1-.alpha.4 Integrin Interaction," Proc. Natl. Acad. Sci. USA, 92:5714-5718 (Jun. 1995).
Vonderheide, R. H. et al., "Residues within a Conserved Amino Acid Motif of Domains 1 and 4 of VCAM-1 are Required for Binding to VLA-4," The Journal of Cell Biology, 125(1):215-222 (Apr. 1994).
Osborn, L. et al., "Arrangement of Domains, and Amino Acid Residues Required for Binding of Vascular Cell Adhesion Molecule-1 to its Counter-Receptor VLA-4 (.alpha..sub.4 .beta..sub.1)," The Journal of Cell Biology, 124(4):601-608 (Feb. 1994).
Priskin, M. et al., "Structural and Functional Analysis of the Mucosal Vascular Addressin MADCAM-1," Clinical Immunology and Immunopathology, 76(1) (part 2) = S85, 8th International Congress of Mucosal Immunology, San Diego, California, Jul. 17 to Jul 20, 1995.
Renz, M. E., et al., "Structural Requirements for Adhesion of Soluble Recombinant Murine Vascular Cell Adhesion Molecule-1 to .alpha.4.beta.1," The Journal of Cell Biology, 125(6):1395-1406 (Jun. 1994).
Briskin, M., "In Vitro and In Vivo Analysis of MADCAM-1/.alpha.4.beta.7 Adhesive Interactions: Implications for Involvement in Inflammatory Bowel Disease," International Symposium, Molecular Mechanisms of Inflammation, Sep. 6-9, 1995.
Wayner, E. A., "Activation-Dependent Recognition by Hematopoietic Cells of the LDV Sequence in the V Region of Fibronectin," The Journal of Cell Biology, 116(2):489-497 (Jan. 1992).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Inhibitors of MAdCAM-1-mediated interactions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of MAdCAM-1-mediated interactions and methods of use , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of MAdCAM-1-mediated interactions and methods of use will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-169218

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.